⚠ Research and educational use only — not for human consumption. Nothing for sale, no dosing advice. PeptideCompare is non-profit and independent.
Database Suppliers Quality & badges Supplier reviews Encyclopedia Articles Calculator
LONGEVITY TOPICS
NAD+ Precursors Sirtuin Activators Senolytics Autophagy Mitochondrial Hormesis
About FAQ Contact Policy
MONOGRAPH No. 074
SEQUENCE
IGF-1 E-domain variant
MW
~2.9 kDa (C-terminal peptide)
CAS
Not assigned
EU STATUS
Research only
WADA
Prohibited S2
MIN PURITY
≥98% HPLC
💪 Muscle, IGF & Body Composition

MGF — EU research guide.

MGF (Mechano Growth Factor) is a splice variant of IGF-1 produced in skeletal muscle in response to mechanical loading. Its unique E-domain peptide activates muscle stem cells (satellite cells) independently of the IGF-1 receptor.

Last reviewed:

What is MGF?

MGF is produced when mechanical stress on skeletal muscle fibres causes alternative splicing of the IGF-1 pre-mRNA, inserting a 52-nucleotide sequence that shifts the reading frame and produces a unique C-terminal E-domain peptide. This MGF E-domain peptide acts through a receptor distinct from IGF-1R to activate quiescent muscle satellite cells — the stem cells responsible for muscle repair and hypertrophy.

What does the research show?

Local injection in animal models shows activation of satellite cells, myoblast proliferation and enhanced muscle repair after injury. The native peptide has an extremely short half-life (minutes), leading to the development of PEG-MGF for research requiring systemic delivery. MGF and IGF-1 LR3 have complementary mechanisms — MGF activates satellite cells; IGF-1 LR3 drives differentiation and protein synthesis.

EU legal status

Not approved anywhere. WADA-prohibited (S2). Available for muscle biology and satellite cell research only.

WADA-prohibited (S2). Very short half-life limits systemic research applications — PEG-MGF is typically preferred for non-local research. Not for human use. This is a research compound, not a medication.
✓ PeptideCompare lists MGF from EU research vendors. For systemic delivery research, compare with PEG-MGF. Confirm E-domain sequence by mass spec.

Molecular information

Molecular weight
~2.9 kDa (C-terminal peptide)
CAS number
Not assigned

Pharmacokinetics

No established human pharmacokinetic data. Published human PK parameters for this compound are not available; reported data are limited to animal models or absent. No curve is shown, to avoid implying data that does not exist.

MGF across EU suppliers

COA-verified EU vendors · Updated monthly

References

  1. The foundational claim: a synthetic 24-amino-acid C-terminal E-peptide activates muscle satellite cells independently of the IGF-1 receptor. Almost everything marketed about MGF traces back to this single mechanism paper. Yang SY, Goldspink G. FEBS Lett. 2002;522(1–3):156–160. PubMed 12095637
  2. The note that vendor pages leave out: researchers at two pharmaceutical companies tried to reproduce the MGF E-peptide effect on human and mouse myoblasts and found no apparent effect on proliferation or differentiation. A key claimed mechanism did not replicate — the most decision-relevant fact about this peptide. Fornaro M, et al. Am J Physiol Endocrinol Metab. 2014;306(2):E150–E156. PubMed 24253048
  3. A counterweight to that null result: in isolated human muscle cells the 24-aa E-peptide extended the proliferative lifespan of satellite cells from young donors but not from old ones. The literature is genuinely mixed, which is the honest summary — not the uniform picture usually presented. Kandalla PK, Goldspink G, Butler-Browne G, Mouly V. Mech Ageing Dev. 2011;132(4):154–162. PubMed 21377485

Related guides

PeptideCompare AssistantOnline · replies instantly
Hi! I help you quickly find the right page — about legality, COAs, badges or suppliers. No price advice, no dosing.
Try a question
Find a supplier Questions about a peptide? Read our articles Compare prices
Navigation assistant · no medical advice